Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
271.00    4.00 (1.50%)
Bid:
260.00
Ask:
266.00
Spread: 6.00 (2.308%)
Market Cap: £242.70m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

AGM Statement and Q1 Trading Update

1 Nov 2018 07:00

RNS Number : 9329F
Wilmington PLC
01 November 2018
Β 

1 November 2018Β 

Β 

Wilmington plc

('Wilmington', 'the Group' or 'the Company')

AGM Statement and Q1 Trading Update

Β 

Wilmington plc, the provider of information, education and networking services in Risk & Compliance, Healthcare and Professional knowledge areas, today announces a trading update for the three month period to 30 September 2018. This statement is being made ahead of its Annual General Meeting that is taking place later today.

Β 

Trading Update

Β 

In what is traditionally the quietest trading period for the Group, revenue performance in the first quarter has been reasonable, with a mix of performances across the different divisions. Overall revenue reduced 1% on an organic basis (i.e. at constant currencies and after adjusting for acquisitions and disposals) compared to the same period last year. This compares to the 3% organic revenue decline experienced across the prior year.

Β 

On a divisional basis, revenue in the Risk & Compliance division was up 7% organically, with good momentum in the main Compliance business, partly as a result of favourable timing issues that accelerated revenue from Q2 into the first three months this year. In the Healthcare division revenue declined 7% on an organic basis reflecting the reduction in deferred revenue noted in September's full year results announcement, as well as the continued impact of the decision to reduce US networking events to focus on improving profitability. Importantly from the perspective of future revenue progression in Healthcare, new business sales in the first quarter in the UK Healthcare business were up over 2% year on year and early indications for Q2 are that sales are expected to be further up compared to weak comparatives in the prior year. Revenue in the Professional businesses was flat year on year, excluding the impact of Ark, the legal services business that was closed in the first half of last year.Β 

Β 

Profit in the period, as anticipated, was down year on year due to the previously disclosed cost increases and investments made last year. This position was exacerbated slightly by a weaker than expected product mix in Q1 although this is expected to be a timing issue that will reverse over the course of the full year.

Β 

Net debt at 30 September 2018 was Β£44.4m (30 June 2018: Β£39.6m; 30 September 2017: Β£42.4m). The outflow since the start of the year is a function of usual seasonal outflows, and the final earn-out payment for SWAT which was acquired in July 2016.

Β 

Outlook

Β 

There is no change in anticipated trading outlook since the full year 2018 results announcement on 12 September 2018. The overall outcome from the divisional revenue and sales performance in the first quarter gives some early encouragement that momentum across the Group is starting to shift as required to achieve full year revenue and profit expectations. Whilst uncertainties remain within the macro economic environment, the changes in regulations that will come into force in the UK as a result of Brexit are likely to lead to new business opportunities in the second half of the year which will help to underpin our growth plans.

Β 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement this inside information is now considered to be in the public domain.

For further information, please contact:

Wilmington plc

Pedro Ros, Chief Executive Officer

Richard Amos, Chief Financial Officer

Β 

FTI Consulting

Charles PalmerΒ / Dwight Burden / Leah Dudley

020 7422 6800

Β 

Β 

Β 

020 3727 1000

Β 

Β 

Notes to Editors

Wilmington plc is the recognised knowledge leader and partner of choice for information, education and networking in Risk & Compliance, Healthcare and Professional areas. Wilmington employs close to 1,000 people and has customers in 120 countries. Wilmington plc is a premium listed company on the main market of the London Stock Exchange.

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
MSCEAKEFDLLPFFF
Date   Source Headline
1st Mar 20171:58 pmRNSVoting Rights and Capital
24th Feb 20172:29 pmRNSDirector/PDMR Shareholding
23rd Feb 20179:36 amRNSInterim Results - Update
23rd Feb 20177:00 amRNSInterim Results
1st Feb 20171:10 pmRNSVoting Rights and Capital
1st Feb 20177:00 amRNSCompletion of Health Service Journal
19th Jan 20177:04 amRNSAcquisition of Health Service Journal
18th Jan 20175:08 pmRNSHolding(s) in Company
17th Jan 20174:43 pmRNSHolding(s) in Company
12th Jan 20179:00 amRNSNotice of Interim Results
3rd Jan 201712:20 pmRNSTotal Voting Rights and Capital
16th Dec 20163:22 pmRNSHolding(s) in Company
1st Dec 20167:00 amRNSVoting Rights and Capital
3rd Nov 20164:03 pmRNSResult of AGM
3rd Nov 20167:00 amRNSAGM and Q1 Trading update
1st Nov 20167:00 amRNSVoting Rights and Capital
17th Oct 201612:53 pmRNSHolding(s) in Company
3rd Oct 201610:05 amRNSVoting Rights and Capital
21st Sep 20162:48 pmRNSDirector/PDMR Shareholdings
20th Sep 201611:54 amRNSShare Awards
16th Sep 20164:31 pmRNSReplacement: Share Awards and Options
16th Sep 20169:10 amRNSShare Awards and Options
14th Sep 20167:00 amRNSFinal Results
2nd Sep 20161:48 pmRNSHolding(s) in Company
1st Sep 20169:39 amRNSVoting Rights and Capital
11th Aug 201610:31 amRNSNotice of Final Results
1st Aug 20169:44 amRNSVoting Rights and Capital
21st Jul 20169:41 amRNSHolding(s) in Company
20th Jul 20167:00 amRNSAcquisition of SWAT
1st Jul 20167:00 amRNSVoting Rights and Capital
10th Jun 20165:04 pmRNSHolding(s) in Company
1st Jun 201611:55 amRNSVoting Rights and Capital
23rd May 201611:57 amRNSHolding(s) in Company
12th May 20167:00 amRNSInterim Management Statement
4th May 20164:05 pmRNSHolding(s) in Company
4th May 20163:54 pmRNSHolding(s) in Company
3rd May 201610:03 amRNSTotal Voting Rights
29th Apr 20169:33 amRNSChange of Company Secretary
1st Apr 20169:33 amRNSTotal Voting Rights
29th Mar 20167:00 amRNSAcquisition
18th Mar 20163:10 pmRNSHolding(s) in Company
11th Mar 20162:03 pmRNSDirector/PDMR Shareholding
1st Mar 20164:37 pmRNSTotal Voting Rights
24th Feb 20167:00 amRNSInterim Results
1st Feb 20169:37 amRNSTotal Voting Rights
19th Jan 20167:00 amRNSAcquisition
15th Jan 20169:52 amRNSHolding(s) in Company
12th Jan 201610:54 amRNSNotification of Interim Results
4th Jan 201611:12 amRNSTotal Voting Rights
17th Dec 20157:00 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.